Cargando…
Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma
epatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality worldwide. Currently, the prevention and treatment of HCC remains a major challenge. As a traditional Chinese medicine (TCM) formula, Ruangan Lidan decoction (RGLD) has been proved to own the effect of relieving HCC...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791079/ https://www.ncbi.nlm.nih.gov/pubmed/36578460 http://dx.doi.org/10.1155/2022/2940654 |
_version_ | 1784859320027971584 |
---|---|
author | Chen, Cuilan Liang, Ting Wu, Qihui Zhou, Zheyi Zhang, Mingmin Feng, Dongshan Tao, Jingrui Si, Tao Cai, Min |
author_facet | Chen, Cuilan Liang, Ting Wu, Qihui Zhou, Zheyi Zhang, Mingmin Feng, Dongshan Tao, Jingrui Si, Tao Cai, Min |
author_sort | Chen, Cuilan |
collection | PubMed |
description | epatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality worldwide. Currently, the prevention and treatment of HCC remains a major challenge. As a traditional Chinese medicine (TCM) formula, Ruangan Lidan decoction (RGLD) has been proved to own the effect of relieving HCC symptoms. However, due to its biological effects and complex compositions, its underlying mechanism of actions (MOAs) have not been fully clarified yet. In this study, we proposed a pharmacological framework to systematically explore the MOAs of RGLD against HCC. We firstly integrated the active ingredients and potential targets of RGLD. We next highlighted 25 key targets that played vital roles in both RGLD and HCC disease via a protein-protein interaction (PPI) network and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Furthermore, an ingredient-target network of RGLD consisting of 216 ingredients with 306 targets was constructed, and multilevel systems pharmacology analyses indicated that RGLD could act on multiple biological processes related to the pathogenesis of HCC, such as cellular response to hypoxia and cell proliferation. Additionally, integrated pathway analysis of RGLD uncovered that RGLD might treat HCC through regulating various pathways, including MAPK signaling pathway, PI3K/Akt signaling pathway, TNF signaling pathway, and ERBB signaling pathway. Survival analysis results showed that HCC patients with low expression of VEGFA, HIF1A, CASP8, and TOP2A were related with a higher survival rate than those with high expression, indicating the potential clinical significance for HCC. Finally, molecular docking results of core ingredients and targets further proved the feasibility of RGLD in the treatment of HCC. Overall, this study indicates that RGLD may treat HCC through multiple mechanisms, which also provides a potential paradigm to investigate the MOAs of TCM prescription. |
format | Online Article Text |
id | pubmed-9791079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-97910792022-12-27 Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma Chen, Cuilan Liang, Ting Wu, Qihui Zhou, Zheyi Zhang, Mingmin Feng, Dongshan Tao, Jingrui Si, Tao Cai, Min Comput Math Methods Med Research Article epatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality worldwide. Currently, the prevention and treatment of HCC remains a major challenge. As a traditional Chinese medicine (TCM) formula, Ruangan Lidan decoction (RGLD) has been proved to own the effect of relieving HCC symptoms. However, due to its biological effects and complex compositions, its underlying mechanism of actions (MOAs) have not been fully clarified yet. In this study, we proposed a pharmacological framework to systematically explore the MOAs of RGLD against HCC. We firstly integrated the active ingredients and potential targets of RGLD. We next highlighted 25 key targets that played vital roles in both RGLD and HCC disease via a protein-protein interaction (PPI) network and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Furthermore, an ingredient-target network of RGLD consisting of 216 ingredients with 306 targets was constructed, and multilevel systems pharmacology analyses indicated that RGLD could act on multiple biological processes related to the pathogenesis of HCC, such as cellular response to hypoxia and cell proliferation. Additionally, integrated pathway analysis of RGLD uncovered that RGLD might treat HCC through regulating various pathways, including MAPK signaling pathway, PI3K/Akt signaling pathway, TNF signaling pathway, and ERBB signaling pathway. Survival analysis results showed that HCC patients with low expression of VEGFA, HIF1A, CASP8, and TOP2A were related with a higher survival rate than those with high expression, indicating the potential clinical significance for HCC. Finally, molecular docking results of core ingredients and targets further proved the feasibility of RGLD in the treatment of HCC. Overall, this study indicates that RGLD may treat HCC through multiple mechanisms, which also provides a potential paradigm to investigate the MOAs of TCM prescription. Hindawi 2022-12-17 /pmc/articles/PMC9791079/ /pubmed/36578460 http://dx.doi.org/10.1155/2022/2940654 Text en Copyright © 2022 Cuilan Chen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Chen, Cuilan Liang, Ting Wu, Qihui Zhou, Zheyi Zhang, Mingmin Feng, Dongshan Tao, Jingrui Si, Tao Cai, Min Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma |
title | Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma |
title_full | Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma |
title_fullStr | Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma |
title_full_unstemmed | Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma |
title_short | Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma |
title_sort | systems pharmacology-based strategy to investigate the mechanism of ruangan lidan decoction for treatment of hepatocellular carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791079/ https://www.ncbi.nlm.nih.gov/pubmed/36578460 http://dx.doi.org/10.1155/2022/2940654 |
work_keys_str_mv | AT chencuilan systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma AT liangting systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma AT wuqihui systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma AT zhouzheyi systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma AT zhangmingmin systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma AT fengdongshan systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma AT taojingrui systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma AT sitao systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma AT caimin systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma |